tissue to provide a microbiologic diagnosis. These procedures can lead to high morbidity in patients and add to healthcare costs. Here we describe a novel next-generation sequencing assay that was used to detect pathogen-derived cell-free DNA in peripheral blood of patients with biopsy-proven invasive fungal infections. The non-invasive nature of this approach could provide rapid, actionable treatment information for invasive fungal infections when a biopsy is not possible.
Introduction
Invasive fungal infections (IFI) are associated with significant morbidity and mortality in immunocompromised patients, especially those with prolonged neutropenia, allogeneic hematopoietic stem cell transplant (HSCT), solid organ transplants (SOT), prolonged corticosteroids, acquired immunodeficiency syndrome (AIDS), and chronic granulomatous disease (CGD) (Patterson et al., 2016) .
IFIs result in increased morbidity and mortality for both solid organ and stem-cell transplant patients.
Patients with an IFI have 5-fold increased mortality, an additional 19.2 days of hospital stay, and $55,400 in additional costs compared to patients without an IFI (Menzin et al., 2009) . Given the high morbidity associated with IFIs, one common approach is to use empiric broad antifungal treatment in patients with persistent fevers after 4-7 days and no identified source, in addition to broad-spectrum antibacterials (Pizzo et al., 1982) . The diagnostic evaluation includes extensive imaging to identify a source for the cause of the fever. If a potential deep infection is identified, an invasive biopsy is considered for definitive diagnosis. While this strategy has been employed by many centers, this empiric approach risks overtreatment, with its associated side-effects. Also, invasive biopsies can be costly and have high morbidity. In order to move away from reliance on empiric therapy, management strategies have increasingly relied on non-invasive diagnostic tests to help guide targeted antifungal therapy (Pagano et al., 2010) .
The current diagnostic paradigm for invasive fungal disease (IFD) includes categories for proven, probable, and possible disease (De Pauw et al., 2008) . These classifications integrate clinical, radiographic, and microbiologic criteria and have been used to guide empiric treatment. Proven IFD requires documented fungal disease by culture, histopathology, or direct microscopic examination of biopsy tissue. However, with the increased usage of serum antigen biomarkers such as Aspergillus galactomannan, many patients fall into the probable category, which is defined by clinical findings and additional laboratory evidence. While this provides some directional suggestions that an invasive mold is Liquid biopsy for fungal disease present, it does not provide species-level identification of the organism which can be critical for guiding therapy. In addition, both the Aspergillus galactomannan and beta-D-glucan tests have inadequate sensitivity for non-Aspergillus molds including Rhizopus, Mucor, Fusarium, and Scedosporium (Lamoth et al., 2012) which are increasingly important causes of IFIs (Douglas et al., 2016 , Petrikkos et al., 2012 .
Given the limitations of current diagnostic technology, there is a need for timely, non-invasive, unbiased methods to detect invasive fungal infections particularly in immunocompromised patients (Fishman, 2007 , Tomblyn et al., 2009 .
We have employed a technique that uses open-ended next-generation sequencing (NGS) of cell-free plasma to detect pathogen DNA (Abril et al., 2016 , De Vlaminck et al., 2015 . Cell-free DNA (cfDNA) are small fragments of circulating DNA in the cell-free compartment of blood (Mandel and Metais, 1948) .
NGS and analysis of these DNA fragments, which are derived from dead and dying cells, has been an active area of research and development in many fields of medicine. For example, NGS of cfDNA has been used to diagnose fetal chromosomal defects by detecting fetal cell-free DNA in maternal circulation (Fan et al., 2008) . Similarly, NGS has been used to monitor solid organ rejection and tumors by detecting organ-or tumor-derived cell-free DNA in blood (Snyder et al., 2011) . Given that the estimated half-life of cfDNA in circulation is less than two hours (Diehl et al., 2008) , this approach is uniquely suited to diagnose active infections where there are ongoing dynamics between the pathogen and the immune system. Here we describe a novel application of NGS for non-invasive detection of pathogen-derived cellfree plasma DNA in patients with invasive fungal infections.
Methods

Ethics
Liquid biopsy for fungal disease This study was approved by the Stanford University Institutional Review Board (IRB). Discarded plasma samples were collected under a waiver of the informed consent requirement as allowed by the IRB.
Patient samples
Plasma was collected at Stanford University hospital between 3-22-2015 and 8-7-2015. Patient infection was confirmed either by standard fungal culture-based methods or targeted ribosomal locus sequencing for fungi (Gomez et al., 2017) . After confirmation of infection, surplus EDTA plasma from clinical testing (complete blood count) was retrieved from the clinical laboratory. Samples were centrifuged, aliquoted, and stored at -80°C for future analysis. Samples and clinical data including confirmed infections were sent to Karius, Inc (Redwood City, CA).
Sample preparation and next-generation sequencing
Plasma samples were thawed, centrifuged at 16,000 rcf for 10 minutes, and spiked with a known concentration of synthetic DNA molecules for quality control purposes. Cell-free DNA was extracted from 0.5 mL plasma using a magnetic bead-based method (Omega Biotek, Norcross, GA). DNA libraries for sequencing were constructed using a modified Ovation ® Ultralow System V2 library preparation kit (NuGEN, San Carlos, CA). Negative controls (buffer only instead of plasma) and positive controls (healthy plasma spiked with a known mixture of microbial DNA fragments) were processed alongside patient samples in every batch to ensure that no sporadic environmental contamination was introduced into the assay. Samples were multiplexed with other samples and sequenced on an Illumina NextSeq ® 500. On average 45 million reads were obtained for each sample.
Analysis Pipeline
Primary sequencing output files were processed using bcl2fastq (v2.17.1.14) to generate the demultiplexed sequencing reads files. Reads were filtered based on sequencing quality and trimmed based Liquid biopsy for fungal disease on partial or full adapter sequence. The bowtie2 (version 2.2.4) method was used to align the remaining reads against Karius' human and synthetic-molecules references. Sequencing reads that exhibited strong alignment against the human references or the synthetic molecule references were collected and filtered out from further analysis. The remaining reads were aligned against Karius' proprietary micro-organism reference database using NCBI-blast (version 2.2.30). A mixture model was used to assign a likelihood to the complete collection of sequencing reads that includes the read sequence probabilities and the (unknown) abundances of each taxon in the sample. An expectation-maximization algorithm was applied to compute the maximum likelihood estimate of each taxon abundance. To determine whether the levels observed in the samples exceeded those expected to originate from the environment alone, a Poisson model parameterized by the estimated background abundances was applied. Only taxa that rejected this null hypothesis at high significance levels were reported and included in downstream analyses. The entire process from DNA extraction through analysis was typically completed within 28 hours. Assuming that shipping from a hospital can take up to 24 hours, results would be available to an ordering clinician in 2-3 days.
Results
Nine subjects were identified with proven invasive fungal infection. Patients had documented fungal infections from a variety of sources including lung, mediastinal lymph node, heart, brain, sternum, and small bowel (Table 1) . Fungal infection was identified either by fungal culture or targeted fungal ribosomal locus sequencing (Gomez et al., 2017) .
In seven out of nine cases, plasma NGS testing detected the same fungus identified from the biopsy tissue at the genus level. In some cases, conventional microbiology identified molds only to the genus level (e.g.
Rhizopus species). The fungi identified by plasma NGS included Aspergillus terreus and non-Aspergillus molds including Scedosporium, Rhizopus, and Cunninghamella.
In one case, plasma NGS identified Aspergillus lentulus while conventional microbiology identified the organism as Aspergillus fumigatus species complex. A. lentulus is morphologically identical to A. fumigatus, shares 91% sequence homology, and both belong to the Aspergillus fumigatus species complex with A. lentulus showing decreased susceptibility to many azoles (Balajee et al., 2005) . This instance highlights the importance of species-level identification of invasive fungal infections.
In cases where plasma NGS testing did not identify the causal IFI organism, this could be due to the delayed timing of plasma sample collection relative to the biopsy procedure. In one case, the plasma sample was obtained 20 days after the biopsy procedure, after at least 15 days of anti-Aspergillus therapy.
While the kinetics of fungal DNA in plasma have not been definitively established, there are data from blood Aspergillus PCR indicating that the signal may wane >7 days of treatment (Imbert et al., 2016) . In the other negative case, Aspergillus fumigatus sequences were present in the raw data but they numbered below the read threshold required for a positive test result. In both cases, Aspergillus galactomannan tests were positive at the approximate time of plasma sampling.
In six of nine patients, multiple organisms were identified by plasma NGS. This included detection of cytomegalovirus, human herpes simplex virus-1, and torque tenovirus, a likely non-pathogenic virus that is present with increasing immunocompromised states (De Vlaminck et al., 2013) . Bacteria were also detected in four patients including Staphylococcus epidermidis, Pseudomonas aeruginosa, Mycobacterium mageritense, and Mycobacterium abscessus. The presence of these organisms could not be confirmed as the cultures sent did not reveal these organisms and/or the appropriate culture was not sent (e.g. AFB culture) although both Mycobacteria are rapidly growing and can grow on routine media.
Discussion
In this study, we demonstrate the use of sequencing of cell-free plasma to non-invasively detect fungal DNA in patients with proven invasive fungal infection. This technique identified molds at the species Liquid biopsy for fungal disease level from a variety of body locations showing the ability of cell-free plasma to integrate information from many organs. This approach, in conjunction with radiographic data and other clinical data, can help target antifungal therapy without the need for an invasive biopsy procedure and its associated morbidity.
Furthermore, increased breadth of detection allows for identification of a wide range of pathogens including both Aspergillus and non-Aspergillus molds. Of note, this open-ended approach can also potentially identify organisms that can mimic IFIs such as Nocardia spp and Toxoplasma gondii.
Despite the availability of a number of new antifungal therapies, invasive fungal infections remain a major cause of morbidity and mortality in immunocompromised patients. This is likely due to both an increase in the intensity of immunosuppressive regimens being used, as well as the widespread use of Aspergillus-active antifungal prophylaxis which has been associated with a both a rise in antifungalresistant organisms (Perlin et al., 2017) and an increase in IFIs due to non-Aspergillus molds such as the Zygomycetes (Ito et al., 2010) . These molds, such as Fusarium spp, Scedosporium spp, and the Mucorales are commonly multidrug resistant making precise identification imperative. Given the wide diversity of pathogenic fungi, there is a critical need for rapid, non-invasive detection of species-level identification of these invasive infections to help guide specific antifungal therapy. , 2008) . Although galactomannan has a reported sensitivity of around 70% in hematologic malignancy and stem-cell transplant patients, its performance in other immunocompromised patients such as solid-organ transplant or primary immunodeficiency patients is much worse (Patterson et al., 2016) . The major limitation of the use of galactomannan and beta-D glucan is their inability to detect the wide range of fungi that can cause IFIs; including Rhizopus, Mucor, Fusarium, and Scedosporium. Anti-fungal Liquid biopsy for fungal disease treatment or prophylaxis can also decrease the level of circulating galactomannan (Marr et al., 2004) .
Non-invasive biomarkers for IFI including the
Fungal DNA levels in plasma may also be affected by antifungal treatment. Studies of Aspergillus PCR have demonstrated that Aspergillus DNA in serum remains relatively stable for the first week after treatment, and clearance by 2-3 weeks may be associated with favorable treatment outcomes (Imbert et al., 2016) . Furthermore, in a study of urine cfDNA for tuberculosis, pathogen cfDNA increased with treatment (Labugger I et al., 2017) . Further investigation will be needed to understand the potentially unique biologic variances of different organisms and to better understand the effects of antifungal treatment on the dynamics of pathogen cell-free DNA to interpret the performance of plasma NGS in patients with invasive fungal infections.
The potential of NGS for infectious disease diagnosis has been demonstrated in recent publications, including employing NGS on cerebrospinal fluid to diagnose neuroleptospirosis (Wilson et al., 2014) , and direct sequencing of brain tissue to detect potential pathogens in culture-negative neuroinflammatory disorders (Salzberg et al., 2016) . While these applications are promising, they still require an invasive procedure to obtain tissue for diagnosis. This is the first report of a plasma NGS test that can noninvasively identify the causal pathogen in proven IFI. This test may allow for earlier targeting of antifungal therapy and forestall an invasive biopsy, particularly when such a biopsy is delayed or could adversely affect the patient's condition. Since fungal genetic sequences are identified, it may be possible in the future to identify antifungal resistance genes to help further guide therapy.
Conclusions
We describe a novel application of next-generation sequencing of cell-free plasma to detect fungal DNA from deep infection sites. This test was able to detect both Aspergillus and non-Aspergillus molds in patients with proven invasive fungal infection diagnosed with invasive sampling of infected tissue. The use of this non-invasive plasma assay can aid in the diagnosis of deep infections, particularly when an invasive diagnostic procedure is not possible, or in immunocompromised patients where the number of potential pathogens is very large.
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